FdaApplication
NDA 202811
Identifiers
- fda_app_no: NDA202811
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2012-08-30 |
Revenue by product
LINZESS
| Period | Revenue |
|---|---|
| Q2 2026 | $295.0M |
| Q1 2026 | $283.0M |
| Q4 2025 | $175.0M |
| Q3 2025 | $326.0M |
| Q2 2025 | $258.0M |
| Q1 2025 | $148.0M |
| Q4 2024 | $233.0M |
| Q3 2024 | $234.0M |
| Q2 2024 | $221.0M |
| Q1 2024 | $266.0M |
| Q4 2023 | $283.0M |
| Q3 2023 | $288.0M |
| Q2 2023 | $278.0M |
| Q1 2023 | $259.0M |
| Q4 2022 | $269.0M |
| Q3 2022 | $271.0M |
| Q2 2022 | $255.0M |
| Q1 2022 | $240.0M |
| Q4 2021 | $287.0M |
| Q3 2021 | $261.0M |
| Q2 2021 | $268.0M |
| Q1 2021 | $222.0M |
| Q4 2020 | $286.0M |
| Q3 2020 | $248.0M |
| Q2 2020 | $133.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LINZESS | LINACLOTIDE | 72MCG | CAPSULE;ORAL |
| LINZESS | LINACLOTIDE | 145MCG | CAPSULE;ORAL |
| LINZESS | LINACLOTIDE | 290MCG | CAPSULE;ORAL |
3 products